Literature DB >> 11641818

Neuro-ophthalmology of mitochondrial diseases.

V Biousse1, N J Newman.   

Abstract

The afferent and efferent visual pathways within the central nervous system are frequently involved in mitochondrial diseases. Neuro-ophthalmic signs figure prominently and may be the presenting or even sole manifestation of these disorders. The four most common neuro-ophthalmic abnormalities seen in mitochondrial disorders are bilateral optic neuropathy, ophthalmoplegia with ptosis, pigmentary retinopathy, and retrochiasmal visual loss.

Entities:  

Mesh:

Year:  2001        PMID: 11641818     DOI: 10.1055/s-2001-17945

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  5 in total

1.  Retinal function and structure in Ant1-deficient mice.

Authors:  M Joseph Phillips; Sarah Webb-Wood; Amanda E Faulkner; Seema B Jabbar; Valerie Biousse; Nancy J Newman; Vi T Do; Jeffrey H Boatright; Douglas C Wallace; Machelle T Pardue
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-29       Impact factor: 4.799

Review 2.  Approach to a patient with blepharoptosis.

Authors:  Samira Yadegari
Journal:  Neurol Sci       Date:  2016-06-21       Impact factor: 3.307

3.  Orbital magnetic resonance imaging of extraocular muscles in chronic progressive external ophthalmoplegia: specific diagnostic findings.

Authors:  Maria Carolina Ortube; Rahul Bhola; Joseph L Demer
Journal:  J AAPOS       Date:  2006-10       Impact factor: 1.220

4.  Mitochondrial DNA abnormalities in ophthalmological disease.

Authors:  Grainne S Gorman; Robert W Taylor
Journal:  Saudi J Ophthalmol       Date:  2011-02-18

5.  Paediatric single mitochondrial DNA deletion disorders: an overlapping spectrum of disease.

Authors:  Alexander Broomfield; Mary G Sweeney; Cathy E Woodward; Carl Fratter; Andrew M Morris; James V Leonard; Lara Abulhoul; Stephanie Grunewald; Peter T Clayton; Michael G Hanna; Joanna Poulton; Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2014-10-29       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.